Evaluation of olopatadine hydrochloride nasal spray, 0.6%, used in combination with an intranasal corticosteroid in seasonal allergic rhinitis.
LaForce
Craig F
CF
North Carolina Clinical Research, Raleigh, North Carolina 27607, USA. claforce@nccr.com
Carr
Warner
W
Tilles
Stephen A
SA
Chipps
Bradley E
BE
Storms
William
W
Meltzer
Eli O
EO
Edwards
Michael
M
D000281:Administration, Intranasal; D000328:Adult; D000730:Androstadienes / Q000008:administration & dosage* / Q000009:adverse effects; D003990:Dibenzoxepins / Q000008:administration & dosage* / Q000009:adverse effects; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D000068298:Fluticasone; D006633:Histamine Antagonists / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D008875:Middle Aged; D000069605:Olopatadine Hydrochloride; D010793:Phthalazines / Q000008:administration & dosage* / Q000009:adverse effects; D006255:Rhinitis, Allergic, Seasonal / Q000188:drug therapy* / Q000503:physiopathology; D016896:Treatment Outcome; D014456:Ulcer / Q000209:etiology; D014987:Xerostomia / Q000209:etiology
D000730:Androstadienes; D003990:Dibenzoxepins; D006633:Histamine Antagonists; D010793:Phthalazines; D000069605:Olopatadine Hydrochloride; D000068298:Fluticasone; C020976:azelastine